Introduction: The role of cellular immune response in dengue virus infection is not yet fully understood. Only few studies in murine models propose that CD8⁺ T-cells are associated with protection from infection and disease. At the light of recent reports about the protective role of CD8⁺ T-cells in humans and the no correlation between neutralizing antibodies and protection observed in several studies, a vaccine based on cell-mediated immunity constitute an attractive approach. Our group has developed a capsid-based vaccine as nucleocpasid-like particles from dengue-2 virus, which induced a protective CD4⁺ and CD8⁺ cell-mediated immunity in mice, without the contribution of neutralizing antibodies. Materials and Methods: Herein we evaluated the immunogenicity and protective efficacy of this molecule in monkeys. Results: Neither IgG antibodies against the whole virus nor neutralizing antibodies were elicited after the antigen inoculation. However, animals developed a cell-mediated immunity, measured by gamma interferon secretion and cytotoxic capacity. Although only one out of three vaccinated animals was fully protected against viral challenge, a viral load reduction was observed in this group compared with the placebo one. Accordingly, the tetravalent formulation evaluated in mice induced gamma interferon-secreting cells and significant viral load reduction after intracranial challenge. Conclusion: Our results suggest that capsid proteins could be the base on an attractive vaccine against dengue.